U.S. court ruling on MS drug is the latest blow for Teva

(Reuters) – A bitter defeat in a U.S. patents case sent shares in Teva Pharmaceutical Industries plummeting on Tuesday, the latest in a series of setbacks that has investors calling for major changes at the world’s largest generic drugmaker.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *